Nikolaos Sfikas

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Neurostatus-SMARTCARE clinical trial: Enabling health care professionals to assess EDSS for decentralized trials in multiple sclerosis.

Neurostatus-SMARTCARE clinical trial: Enabling health care professionals to assess EDSS for decentralized trials in multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: December 20, 2024

Decentralized Clinical Trials: Scientific Considerations Through the Lens of the Estimand Framework.

Decentralized Clinical Trials: Scientific Considerations Through the Lens of the Estimand Framework.

Journal: Therapeutic innovation & regulatory science

Published: July 17, 2023

Opportunities and challenges with decentralized trials in Neuroscience.

Opportunities and challenges with decentralized trials in Neuroscience.

Journal: Biometrical journal. Biometrische Zeitschrift

Published: December 28, 2022

Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.

Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.

Journal: Current medical research and opinion

Published: June 30, 2015

Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis.

Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis.

Journal: Journal of neurology

Published: June 23, 2015

Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors.

Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors.

Journal: Multiple sclerosis and related disorders

Published: October 08, 2014

No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.

No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.

Journal: Advances in therapy

Published: August 15, 2014

The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis.

The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: May 09, 2014

Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.

Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: October 14, 2013

Quantifying unrecognised replication present in reports of HIV diagnoses.

Quantifying unrecognised replication present in reports of HIV diagnoses.

Journal: Statistics in medicine

Published: November 02, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026